Eli Lilly and Company $LLY
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS145
PHASE 3 / 2-394
RECRUITING73
READOUTS ≤12 MONTHS45
READOUT SLIPPED >6 MO38%
Delay Index: of 98 active trials registered more than a year ago, 37 have moved their primary completion (readout) date by more than 6 months since first registration (median +1.2 months). See all sponsors →
Open Eli Lilly and Company on the live radar map → 📅 $LLY readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| 120 mg LY2784544 NCT01594723 |
P2 | Active, not recruiting | Neoplasms, Hematologic | 110 | 2015-03-20 (+5 mo) |
| MONARCH 3 NCT02246621 |
P3 | Active, not recruiting | Breast Cancer | 493 | 2017-01-31 (-5 mo) |
| MONARCH 2 NCT02107703 |
P3 | Active, not recruiting | Breast Neoplasms | 669 | 2017-02-14 |
| JUNIPER NCT02152631 |
P3 | Active, not recruiting | Non Small Cell Lung Cancer | 453 | 2017-09-15 (+14 mo) |
| Ramucirumab NCT02711553 |
P2 | Active, not recruiting | Biliary Tract Cancer; Metastatic Cancer | 309 | 2018-02-16 (+2 mo) |
| RELAY NCT02411448 |
P3 | Active, not recruiting | Metastatic Non-Small Cell Lung Cancer | 545 | 2019-01-23 (+6 mo) |
| MONARCH plus NCT02763566 |
P3 | Active, not recruiting | Breast Cancer | 463 | 2019-03-29 (-8 mo) |
| monarchE NCT03155997 |
P3 | Active, not recruiting | Breast Cancer | 5637 | 2020-03-16 (-27 mo) |
| LIBRETTO-321 NCT04280081 |
P2 | Active, not recruiting | Solid Tumor; Medullary Thyroid Cancer | 77 | 2021-03-25 (-2 mo) |
| Donanemab NCT04437511 |
P3 | Active, not recruiting | Alzheimer Disease | 1736 | 2023-04-14 (+1 mo) |
| LIBRETTO-431 NCT04194944 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 261 | 2023-05-01 (-7 mo) |
| Baricitinib NCT04088409 |
P3 | Active, not recruiting | Uveitis | 30 | 2023-07-17 (+16 mo) |
| CYCLONE 2 NCT03706365 |
P2/3 | Active, not recruiting | Prostate Cancer | 393 | 2024-01-02 (+28 mo) |
| postMONARCH NCT05169567 |
P3 | Active, not recruiting | Breast Neoplasm; Neoplasm Metastasis | 368 | 2024-02-08 (+6 mo) |
| CYCLONE 3 NCT05288166 |
P3 | Active, not recruiting | Prostatic Neoplasms; Neoplasm Metastasis | 925 | 2024-02-15 (-20 mo) |
| Ixekizumab NCT04527380 |
P3 | Active, not recruiting | Juvenile Psoriatic Arthritis; Enthesitis Related Arthritis | 101 | 2024-02-19 (+11 mo) |
| Donanemab NCT05738486 |
P3 | Active, not recruiting | Alzheimer's Disease; Dementia | 1175 | 2024-05-16 (+2 mo) |
| EMBER-3 NCT04975308 |
P3 | Active, not recruiting | Breast Neoplasms; Neoplasm Metastasis | 874 | 2024-06-24 (+15 mo) |
| LIBRETTO-121 NCT03899792 |
P1/2 | Active, not recruiting | Medullary Thyroid Cancer; Infantile Myofibromatosis | 36 | 2024-11-08 (+36 mo) |
| VIVID-2 NCT04232553 |
P3 | Active, not recruiting | Crohn's Disease | 996 | 2024-11-28 (+13 mo) |
| Abemaciclib NCT05440786 |
P2 | Active, not recruiting | Sarcoma, Ewing; Neoplasm Metastasis | 46 | 2025-01-15 (-2 mo) |
| LIBRETTO-001 NCT03157128 |
P1/2 | Active, not recruiting | Non-Small Cell Lung Cancer; Medullary Thyroid Cancer | 857 | 2025-02-14 (+66 mo) |
| ATTAIN-1 NCT05869903 |
P3 | Active, not recruiting | Obesity; Overweight | 3127 | 2025-07-25 (-2 mo) |
| REBUILD-1 NCT03432286 |
P3 | Active, not recruiting | Episodic Migraine | 533 | 2025-11-14 (+47 mo) |
| REBUILD-2 NCT04616326 |
P3 | Active, not recruiting | Chronic Migraine | 312 | 2025-12-10 (+34 mo) |
| Tirzepatide NCT06037252 |
P2 | Active, not recruiting | Type 2 Diabetes; Obesity | 414 | 2026-01-08 (+12 mo) |
| LIBRETTO-432 NCT04819100 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 152 | 2026-01-12 (-63 mo) |
| ADorable-1 NCT05559359 |
P3 | Active, not recruiting | Atopic Dermatitis; Eczema | 377 | 2026-01-14 (+17 mo) |
| Bimagrumab NCT06643728 |
P2 | Active, not recruiting | Obesity; Overweight | 252 | 2026-01-16 (+4 mo) |
| Mirikizumab NCT03519945 |
P3 | Active, not recruiting | Ulcerative Colitis | 1058 | 2026-03-04 (+30 mo) |
| Tirzepatide NCT06075667 |
P3 | Active, not recruiting | Obesity; Overweight | 160 | 2026-06-02 (+4 mo) |
| Eltrekibart NCT06598943 |
P2 | Active, not recruiting | Ulcerative Colitis; Ulcerative Colitis Chronic | 143 | 2026-08-03 (-16 mo) |
| Retatrutide NCT06260722 |
P3 | Active, not recruiting | Diabetes Mellitus, Type 2 | 1250 | 2026-08-27 (-3 mo) |
| Baricitinib NCT04088396 |
P3 | Active, not recruiting | Systemic Juvenile Idiopathic Arthritis | 58 | 2026-10 (+48 mo) |
| LY3650150 NCT06339008 |
P3 | Active, not recruiting | Perennial Allergic Rhinitis (PAR) | 450 | 2026-10-22 (+17 mo) |
| Retatrutide NCT06297603 |
P3 | Active, not recruiting | Type 2 Diabetes | 320 | 2026-10-26 (+1 mo) |
| LY4515100 NCT07511816 |
P2 | Recruiting | Acute Pain; Molar | 212 | 2026-11 |
| TRIUMPH-5 NCT06662383 |
P3 | Active, not recruiting | Obesity | 800 | 2026-11 (-5 mo) |
| LY3938577 NCT07215312 |
P2 | Active, not recruiting | Diabetes Mellitus, Type 2 | 100 | 2026-11 |
| SURPASS-T1D-1 NCT06914895 |
P3 | Active, not recruiting | Type 1 Diabetes; Obesity | 905 | 2026-11 (-6 mo) |
| SURPASS-T1D-2 NCT06962280 |
P3 | Active, not recruiting | Type 1 Diabetes; Obesity | 465 | 2026-11 (-5 mo) |
| LY3537021 NCT07169851 |
P2 | Recruiting | Nausea; Vomiting | 204 | 2026-12 (+3 mo) |
| RENEW-Smk-1 NCT07223840 |
P2 | Recruiting | Smoking | 222 | 2027-02 |
| Abemaciclib NCT06413706 |
P2 | Active, not recruiting | Glioma | 45 | 2027-02 (-5 mo) |
| ADVANCE NCT06672549 |
P3 | Recruiting | Obesity; Overweight | 125 | 2027-02 |
| SOLARIS-1 NCT07269210 |
P2 | Recruiting | Severe Hypertriglyceridemia | 60 | 2027-03 |
| Macupatide NCT07215559 |
P2 | Active, not recruiting | Obesity; Overweight | 200 | 2027-03 |
| OA07 NCT07641517 |
P2 | Recruiting | Osteoarthritis, Knee; Chronic Pain | 150 | 2027-04 |
| LY3537982 NCT04956640 |
P1/2 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | 540 | 2027-04 (+42 mo) |
| CPMP NCT05986292 |
P2 | Recruiting | Osteoarthritis, Knee; Diabetic Neuropathic Pain | 10000 | 2027-04 |
| BP07 NCT07641504 |
P2 | Recruiting | Chronic Pain; Low Back Pain | 150 | 2027-04 |
| ACHIEVE-RAM NCT07613307 |
P3 | Recruiting | Diabetes Mellitus, Type 2; Diabetes Melletus | 130 | 2027-05 |
| CLARITY-CRP NCT07783802 |
P2 | Recruiting | Atherosclerosis; Cardiovascular Disease | 120 | 2027-05 |
| LY4005130 NCT07533019 |
P2 | Recruiting | Vitiligo; Non-Segmental Vitiligo (NSV) | 66 | 2027-05 |
| LY3650150 NCT06338995 |
P3 | Recruiting | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 510 | 2027-05 (+17 mo) |
| TOPAZ-UC NCT07186101 |
P2 | Recruiting | Ulcerative Colitis | 252 | 2027-05 |
| CAMPFIRE NCT05999994 |
P2 | Recruiting | Neoplasms; Child | 105 | 2027-05 (+12 mo) |
| LY3457263 NCT06897475 |
P2 | Recruiting | Type 2 Diabetes | 200 | 2027-05 (+5 mo) |
| Mirikizumab - Intravenous (IV) NCT07483073 |
P2 | Recruiting | Colitis, Ulcerative; Crohn Disease | 60 | 2027-06 |
| TRIUMPH-8 NCT07232719 |
P3 | Active, not recruiting | Obesity; Overweight | 250 | 2027-06 |
| LY4395089 NCT07483099 |
P2 | Recruiting | Crohn Disease | 60 | 2027-06 |
| LY4005130 NCT07533006 |
P2 | Recruiting | Alopecia Areata | 65 | 2027-06 |
| NP07 NCT07285018 |
P2 | Recruiting | Diabetic Peripheral Neuropathic Pain | 150 | 2027-07 |
| RENEW-IBS-C NCT07545772 |
P2 | Recruiting | Irritable Bowel Syndrome; Constipation | 342 | 2027-07 |
| Orforglipron NCT06993792 |
P3 | Active, not recruiting | Obesity; Overweight | 1400 | 2027-08 (+7 mo) |
| Orforglipron NCT06972459 |
P3 | Active, not recruiting | Obesity; Overweight | 800 | 2027-08 (+7 mo) |
| Orforglipron NCT06972472 |
P3 | Active, not recruiting | Obesity; Overweight | 600 | 2027-08 (+7 mo) |
| Orforglipron NCT06948422 |
P3 | Active, not recruiting | Hypertension | 974 | 2027-09 |
| TRIUMPH-7 NCT07035093 |
P3 | Active, not recruiting | Obesity; Overweight | 586 | 2027-09 |
| LY3305677 NCT06143956 |
P2 | Recruiting | Obesity; Overweight | 1481 | 2027-09 (+33 mo) |
| RENEW-IBS-D NCT07545759 |
P2 | Recruiting | Irritable Bowel Syndrome; Diarrhea | 531 | 2027-09 |
| Macupatide NCT07589608 |
P2 | Recruiting | Overweight; Obesity | 400 | 2027-09 |
| Orforglipron NCT06952530 |
P3 | Active, not recruiting | Hypertension | 487 | 2027-09 |
| Orforglipron NCT06948435 |
P3 | Active, not recruiting | Hypertension; Overweight or Obesity | 487 | 2027-09 |
| SURMOUNT-MMO NCT05556512 |
P3 | Active, not recruiting | Obesity; Overweight | 15374 | 2027-10 |
| Tirzepatide NCT06439277 |
P3 | Recruiting | Obesity; Weight Gain | 300 | 2027-10 (+5 mo) |
| EMBER-4 NCT05514054 |
P3 | Active, not recruiting | Breast Neoplasms | 8000 | 2027-10 |
| RENEW-Scz-1 NCT07410507 |
P2 | Recruiting | Schizophrenia | 450 | 2027-11 |
| Donanemab NCT05026866 |
P3 | Active, not recruiting | Alzheimer Disease | 2996 | 2027-11 (+1 mo) |
| SUNRAY-01 NCT06119581 |
P3 | Recruiting | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | 1264 | 2027-11 (+13 mo) |
| Brenipatide NCT07286175 |
P2 | Recruiting | Bipolar Disorder | 400 | 2027-11 |
| PIKALO-3 NCT07935317 |
P2 | Not yet recruiting | Breast Neoplasms | 120 | 2027-12 |
| Dulaglutide NCT06739122 |
P3 | Recruiting | Type 2 Diabetes | 55 | 2027-12 (+18 mo) |
| Orforglipron NCT06672939 |
P3 | Recruiting | Obesity; Overweight | 150 | 2027-12 (+10 mo) |
| AMAY NCT05509777 |
P3 | Recruiting | Crohn's Disease | 90 | 2027-12 (+17 mo) |
| ADorable-2 NCT05735483 |
P3 | Enrolling by invitation | Atopic Dermatitis; Eczema | 338 | 2027-12 (+17 mo) |
| LY4086940 NCT07890376 |
P2 | Not yet recruiting | Obesity; Overweight | 460 | 2028-01 |
| ENLIGHTEN-2 NCT07282600 |
P3 | Recruiting | Overweight; Obesity | 1035 | 2028-01 |
| Pirtobrutinib NCT06721013 |
P1/2 | Recruiting | Immune Thrombocytopenia (ITP) | 68 | 2028-02 (+12 mo) |
| RENEW-MDD-1 NCT07412756 |
P3 | Recruiting | Depressive Disorder, Major | 1000 | 2028-02 |
| RENEW-Op-1 NCT07420283 |
P2 | Recruiting | Opioid Use Disorder | 465 | 2028-03 |
| BRAVE-AA-PEDS NCT05723198 |
P3 | Recruiting | Areata Alopecia; Alopecia | 595 | 2028-03 (+35 mo) |
| ENLIGHTEN-4 NCT07353931 |
P3 | Recruiting | Osteoarthritis; Overweight or Obesity | 900 | 2028-03 |
| ATTAIN-CN NCT07790861 |
P3 | Not yet recruiting | Obesity; Overweight | 192 | 2028-03 |
| ENLIGHTEN-1 NCT07321886 |
P3 | Recruiting | Obesity; Overweight | 1980 | 2028-03 |
| ENLIGHTEN-3 NCT07369011 |
P3 | Recruiting | Sleep Apnea, Obstructive; Obesity | 800 | 2028-03 |
| RESTRAIN-SUI NCT07202884 |
P3 | Recruiting | Urinary Incontinence,Stress | 1000 | 2028-03 |
| RENEW-ALC-2 NCT07219953 |
P3 | Recruiting | Alcohol Use Disorder | 1100 | 2028-04 |
| TRIUMPH-6 NCT06859268 |
P3 | Active, not recruiting | Obesity | 643 | 2028-04 |
| RENEW-Asthma NCT07219173 |
P2 | Recruiting | Asthma | 531 | 2028-04 |
| RENEW-ALC-1 NCT07219966 |
P3 | Recruiting | Alcohol Use Disorder | 1100 | 2028-04 |
| COMMIT-UC NCT06937086 |
P3 | Recruiting | Ulcerative Colitis; Obesity or Overweight | 350 | 2028-04 |
| ATTAIN-OA PAIN NCT07153471 |
P3 | Active, not recruiting | Osteoarthritis | 800 | 2028-04 |
| Donanemab NCT05508789 |
P3 | Active, not recruiting | Alzheimer Disease; Dementia | 1500 | 2028-05 (+34 mo) |
| RENEW-COPD NCT07759245 |
P2 | Recruiting | Pulmonary Disease, Chronic Obstructive | 606 | 2028-05 |
| COMMIT-CD NCT06937099 |
P3 | Recruiting | Crohn's Disease; Obesity or Overweight | 290 | 2028-05 |
| RENEW-MDD-3 NCT07928245 |
P2 | Not yet recruiting | Major Depressive Disorder | 330 | 2028-05 |
| ENLIGHTEN-6 NCT07392190 |
P3 | Recruiting | Overweight; Obesity | 900 | 2028-06 |
| ATTAIN-PAD NCT07223593 |
P3 | Recruiting | Peripheral Arterial Disease | 1205 | 2028-06 |
| FORAY NCT07827612 |
P2 | Not yet recruiting | Urinary Bladder Neoplasms; Urologic Neoplasms | 161 | 2028-07 |
| Baricitinib NCT07222332 |
P3 | Recruiting | Diabetes Mellitus, Type 1 | 300 | 2028-07 |
| Donanemab NCT07589595 |
P2 | Recruiting | Cognitive Dysfunction; Lewy Body Disease | 350 | 2028-08 |
| TRIUMPH-9 NCT07357415 |
P3 | Active, not recruiting | Obesity; Overweight | 600 | 2028-10 |
| AAVAnc80-hOTOF via Akouos Delivery Device NCT05821959 |
P3 | Recruiting | Sensorineural Hearing Loss, Bilateral | 48 | 2028-10 (+6 mo) |
| Olomorasib NCT07814417 |
P2 | Not yet recruiting | Colorectal Neoplasms | 50 | 2028-11 |
| FRAmework-01 NCT07213804 |
P3 | Recruiting | Ovarian Neoplasms; Fallopian Tube Neoplasms | 1630 | 2028-11 (+7 mo) |
| RENEW-MDD- 2 NCT07775300 |
P3 | Recruiting | Depressive Disorder, Major | 1000 | 2028-12 |
| preEMBER NCT07287098 |
P2 | Recruiting | Breast Neoplasms | 600 | 2029-01 |
| Retatrutide NCT06383390 |
P3 | Active, not recruiting | Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD) | 10000 | 2029-02 |
| Lepodisiran Sodium NCT06292013 |
P3 | Active, not recruiting | Atherosclerotic Cardiovascular Disease (ASCVD); Elevated Lp(a) | 17300 | 2029-03 |
| Remternetug NCT06653153 |
P3 | Active, not recruiting | Alzheimer's Disease | 1400 | 2029-04 |
| LY4064809 NCT07174336 |
P3 | Recruiting | Breast Neoplasms; Neoplasm Metastasis | 800 | 2029-05 |
| SUNRAY-02 NCT06890598 |
P3 | Recruiting | Carcinoma, Non-Small-Cell Lung | 700 | 2029-05 (+12 mo) |
| ACTIVATE-HFpEF NCT07920887 |
P2 | Not yet recruiting | Heart Failure, Diastolic; Diastolic Heart Failure | 540 | 2029-07 |
| AAVAnc80-antiVEGF via Akouos Delivery Device NCT06517888 |
P1/2 | Recruiting | Vestibular Schwannoma | 27 | 2029-08 |
| ATTAIN-NOW NCT07794579 |
P3 | Recruiting | Overweight; Prediabetic State | 2001 | 2029-08 |
| Donanemab NCT07602582 |
P3 | Recruiting | Alzheimer Disease; Dementia | 550 | 2029-09 |
| FORAGER-2 NCT07218380 |
P3 | Recruiting | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms | 450 | 2029-10 |
| AMPLIFY-2 NCT07881458 |
P3 | Recruiting | Obesity; Overweight | 1000 | 2029-10 |
| AMPLIFY-1 NCT07881432 |
P3 | Not yet recruiting | Obesity | 2115 | 2029-10 |
| ENLIGHTEN-10 NCT07900633 |
P3 | Not yet recruiting | Obesity; Overweight | 3000 | 2029-11 |
| ACCLAIM-CTA NCT07613294 |
P3 | Recruiting | Atherosclerosis; Cardiovascular Diseases | 252 | 2029-12 |
| Tirzepatide NCT07817875 |
P3 | Recruiting | Obesity | 150 | 2029-12 |
| ACHIEVE-PEDS NCT07668336 |
P3 | Recruiting | Diabetes Mellitus, Type 2 | 170 | 2030-03 |
| Donanemab NCT07571161 |
P3 | Recruiting | Alzheimer Disease | 140 | 2030-04 |
| Pirtobrutinib NCT07162181 |
P2 | Active, not recruiting | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | 13 | 2030-05 |
| EMERALD-3 NCT07415044 |
P2 | Recruiting | Ulcerative Colitis (UC); Ulcerative Colitis, Active Moderate | 1431 | 2030-06 |
| PIKALO-1 NCT05768139 |
P1/2 | Recruiting | Breast Cancer; Solid Tumors, Adult | 880 | 2030-07 (+49 mo) |
| Tirzepatide NCT07165028 |
P3 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease | 4500 | 2030-08 |
| SHINE-ON NCT04844606 |
P3 | Recruiting | Ulcerative Colitis; Ulcerative Colitis Chronic | 150 | 2030-12 (+38 mo) |
| MOVE-Lp(a) NCT07157774 |
P3 | Recruiting | Elevated Lp(a); Atherosclerotic Cardiovascular Disease (ASCVD) | 10450 | 2031-03 |
| JUVE-X NCT03773965 |
P3 | Recruiting | Juvenile Idiopathic Arthritis | 190 | 2031-07 (+46 mo) |
| BARICADE-DELAY NCT07222137 |
P3 | Recruiting | Diabetes Mellitus, Type 1 | 150 | 2031-07 |
| Orforglipron NCT07241390 |
P3 | Recruiting | Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease | 7140 | 2031-08 |
| ANCHOR-AD NCT07142954 |
P3 | Recruiting | Alzheimer Disease | 3400 | 2033-07 |